Lucentis and Dry mouth - a phase IV clinical study of FDA data

Summary:

Dry mouth is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Heparin, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Dry mouth when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Dry mouth?

Dry mouth is found to be associated with 2,090 drugs and 2,492 conditions by eHealthMe. Check the latest studies of Dry mouth.

On Jul, 08, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 17 people (0.07%) have Dry mouth.

Among these 17 people:

How long have people been on Lucentis when they have Dry mouth? *

What is the gender of people who have Dry mouth when taking Lucentis? *

female: 94.12 %
male: 5.88 %

What is the age of people who have Dry mouth when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Dry mouth? *

Weight Decreased: 6 people, 35.29%
Nausea And Vomiting: 6 people, 35.29%
Nausea (feeling of having an urge to vomit): 6 people, 35.29%
Diarrhea: 5 people, 29.41%
Fatigue (feeling of tiredness): 5 people, 29.41%
Stress And Anxiety: 5 people, 29.41%
Paleness (unusual lightness of skin colour): 4 people, 23.53%
Dry Eyes (lack of adequate tears): 4 people, 23.53%
Pain: 4 people, 23.53%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 23.53%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 3 people, 17.65%
Metastases To Bone (cancer spreads to bone): 2 people, 11.76%
Breast Cancer Metastatic: 2 people, 11.76%
Retinal Detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue): 1 person, 5.88%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 1 person, 5.88%
Eye Haemorrhage (bleeding in the eye): 1 person, 5.88%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 1 person, 5.88%
Diabetes: 1 person, 5.88%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 5.88%
Age-Related Macular Degeneration: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Dry mouth?

- Check whether Dry mouth is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Dry mouth treatments and more:

Dry mouth (97,956 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dry mouth:

Dry mouth (2,090 drugs)

Browse all the conditions that are associated with Dry mouth:

Dry mouth (2,492 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.